Colorado attained a number of key financings, acquisitions and expansions in its bioscience industry during 2014. April Giles, President and CEO of the Colorado BioScience Association says: "We’ve seen a number of exciting deals come to fruition in our Colorado bioscience community during 2014, which strengthens our state’s position as a national industry leader. We’re thrilled that CBSA has continued to play a significant role in promoting Colorado as a dynamic region for bioscience innovation and investment.”
Highlighted Financings and Acquisitions in 2014 Include:
* Terumo BCT broke ground on a 120,000-square-foot global headquarters building – April 1, 2014
Terumo BCT is building a 120,000-square-foot Global Headquarters building on its Lakewood campus. In 2015,
when the building opens, Terumo BCT will occupy 90,000 square feet, leaving the additional space available for future growth and development. When complete, it will accommodate an estimated 400 associates.
http://coloradocommunitymedia.com/stories/A-global-home,151084
* BioScience Park Center 2 groundbreaking adding 112,000 square foot building – April 4, 2014
The Fitzsimons Redevelopment Authority (FRA) and CU's Bioengineering program, design a multipurpose building for education, research and clinical care, with an added entrepreneurial element of private biosciences companies. Bioengineering students will have classes on the first two floors of the four-story building, and from there, the students will move up a floor and practice what they have learned and then move up again to begin their own commercial bioscience company on the top floor.
http://www.ucdenver.edu/about/newsroom/newsreleases/Pages/Bioscience-2-groundbreaking-April-2014.aspx
* Spectranetics acquires California based AngioScore Inc. for $230 million in cash – June 30, 2014
Colorado Springs based Spectranetics Corporation (Nasdaq:SPNC) announced that it completed the acquisition of AngioScore Inc., a leading developer, manufacturer and marketer of cardiovascular, specialty balloons, for $230 million in cash, along with additional contingent commercial and regulatory milestone payments.
http://globenewswire.com/news-release/2014/05/27/639682/10083292/en/Spectranetics-Announces-Agreement-to-Acquire-AngioScore-Inc.html
* Covidien to be acquired by Medtronic for $42.9B – June 16, 2014
Medtronic announced it will pay $42.9 billion in cash and stock to acquire Covidien and its medical-device lines in a deal expected to close in the fourth quarter or early 2015. Medtronic in Lousiville, and Covidien in Boulder, combined have over 2000 jobs in Colorado.
http://www.massdevice.com/news/blockbuster-medtronic-43b-deal-acquire-covidien
* Clovis Oncology to offer $200M in convertible senior notes in private placement to investors – Sept 3, 2014
Boulder based Clovis Oncology Inc. announced it intended to offer $200 million aggregate principal amount of its convertible senior notes due 2021 in a private placement to qualified international buyers.
http://innovationews.com/science/bioscience/clovis-oncology-to-offer-200m-in-convertible-senior-notes-in-private-placement-to-foreign-investors
* InDevR Wins $14.7M Barda Contract for Cutting-Edge Influenza Diagnostic – September 15, 2014
Boulder based InDevR announced that it signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to complete product development of their unique influenza diagnostic, FluChip-8G, which is capable of rapidly genotyping influenza viruses directly from clinical samples.
http://www.marketwired.com/press-release/-1947252.htm
* SomaLogic announces Novartis agreement extension, equity investment – October 20, 2014
Boulder based SomaLogic, Inc. announced that Novartis has extended its multi-year research agreement for the development and application of SomaLogic’s unique proteomics technology to Novartis’ drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension.
http://www.somalogic.com/Resources/News-Events/News/2014/SomaLogic-announces-Novartis-agreement-extension,.aspx
* N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing – November 19, 2014
Boulder based N30 Pharmaceuticals, Inc. (“N30 Pharma”), a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), has raised $30 million in a mezzanine round of financing. Proceeds from the financing will primarily be used to advance the Company’s clinical trial program. New investors include Wellington Management, RA Capital Management, LLC, Jennison Associates LLC (on behalf of certain clients), Rock Springs Capital Management LP, and Sabby Management, LLC, who joined existing investor, Deerfield Management Company.
http://www.prnewswire.com/news-releases/n30-pharmaceuticals-secures-30-million-in-oversubscribed-crossover-financing-283193921.html
Link to the Business Wire release
Link to the Pitch Engine social media newswire
.gif){kind=logo}
.gif){kind=logo}
